{"id":"W4401178837","doi":"10.1182/blood.2024024631","title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Obinutuzumab; Ven; IGHV@; Venetoclax; Internal medicine; Chronic lymphocytic leukemia; Gastroenterology; Chlorambucil; Population; Leukemia; Oncology; Chemotherapy; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003457921,0.0007577961,0.001760054,0.0002444583,0.0003076735,0.0009377786,0.000637221,0.0009638843,0.002321217],"category_scores_gemma":[0.001644577,0.0003181818,0.001817619,0.0003974249,0.000512668,0.0005811116,0.0003152289,0.001931765,0.0003832118],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007429591,"about_ca_system_score_gemma":0.0009668349,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008830029,"about_ca_topic_score_gemma":0.00224137,"domain_scores_codex":[0.9988713,0.0008205359,0.00003833849,0.00009362841,0.00007414949,0.0001020328],"domain_scores_gemma":[0.9985387,0.0004225783,0.0004885588,0.0001111601,0.00007236304,0.0003667015],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.938864,0.005595668,0.00694396,0.00057221,0.002559118,0.0000594142,0.00007589516,0.001123643,0.004159858,0.00009760461,0.001994777,0.03795391],"study_design_scores_gemma":[0.8528277,0.1081375,0.0324292,0.000096517,0.002236647,0.0001456148,0.00003619156,0.0009362183,0.00088854,0.0002023609,0.002029032,0.00003441912],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9872502,0.009152759,0.0003852575,0.0003011401,0.0001296535,0.0006520131,0.001121854,0.0000513408,0.0009556298],"genre_scores_gemma":[0.9911371,0.002965485,0.0008820156,0.000525025,0.0001570046,0.0008974805,0.002252312,0.00002665864,0.001156834],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003457921,"threshold_uncertainty_score":0.01828742,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01833361852785721,"score_gpt":0.3242953708562311,"score_spread":0.3059617523283739,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}